Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2022; 10(35): 13115-13121
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.13115
Systemic combined with intravitreal methotrexate for relentless placoid chorioretinitis: A case report
Lan Luo, Wei-Bin Chen, Ming-Wei Zhao, Heng Miao
Lan Luo, Wei-Bin Chen, Ming-Wei Zhao, Heng Miao, Department of Ophthalmology & Clinical Center of Optometry, Peking University People’s Hospital, Beijing 100044, China
Lan Luo, Wei-Bin Chen, Ming-Wei Zhao, Heng Miao, Eye Diseases and Optometry Institute, Peking University People's Hospital, Beijing 100044, China
Lan Luo, Wei-Bin Chen, Ming-Wei Zhao, Heng Miao, College of Optometry, Peking University Health Science Center, Beijing 100191, China
Lan Luo, Wei-Bin Chen, Ming-Wei Zhao, Heng Miao, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing 100044, China
Author contributions: Luo L, Chen WB, Zhao MW, and Miao H contributed to material preparation, data collection and analysis were performed; Luo L and Chen WB contributed to the main manuscript was written; Miao H provided a critical review of the manuscript; all authors have read the article and approved the final version.
Supported by the National Natural Science Foundation of China, No. 81800847; and the Tenth “Academic Star” project of Peking University People's Hospital, No. RS2018-05.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Heng Miao, MD, Doctor, Department of Ophthalmology & Clinical Center of Optometry, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. sawyer_young@sina.com
Received: October 7, 2022
Peer-review started: October 7, 2022
First decision: October 27, 2022
Revised: November 10, 2022
Accepted: November 24, 2022
Article in press: November 24, 2022
Published online: December 16, 2022
Processing time: 67 Days and 15.3 Hours
Core Tip

Core Tip: Relentless placoid chorioretinitis is a bilateral disease in nature and refractory to corticosteroid monotherapy, which warrants the importance of systemic immunosuppressants given upon diagnosis. Intravitreal methotrexate should also be considered as part of the initial therapy for macula-threatening cases in order to halt progression immediately and preserve visual function.